$13.47
0.45% yesterday
NYSE, Aug 12, 10:00 pm CET
ISIN
VGG111961055
Symbol
BHVN

Biohaven Pharmaceutical Holding Company Ltd. Stock price

$13.47
-0.72 5.07% 1M
-28.65 68.02% 6M
-23.88 63.94% YTD
-23.50 63.57% 1Y
-134.29 90.88% 3Y
-45.93 77.32% 5Y
-4.03 23.03% 10Y
-4.03 23.03% 20Y
NYSE, Closing price Tue, Aug 12 2025
+0.06 0.45%
ISIN
VGG111961055
Symbol
BHVN
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.0b
Net debt
positive
Cash
$322.8m
Shares outstanding
102.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 135.1
EV/Sales
- | 103.2
EV/FCF
negative
P/B
5.3
Financial Health
Equity Ratio
68.8%
Return on Equity
-199.9%
ROCE
-313.1%
ROIC
-3,215.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $10.1m
EBITDA
$-914.8m | $-754.1m
EBIT
$-923.4m | $-817.2m
Net Income
$-888.6m | $-793.4m
Free Cash Flow
$-649.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-71.1% | 14.0%
EBIT
-70.5% | 7.7%
Net Income
-71.8% | 6.3%
Free Cash Flow
-80.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -7,439.1%
EBIT
-
Net
- | -7,827.0%
Free Cash Flow
-
More
EPS
$-8.7
FCF per Share
$-6.4
Short interest
14.9%
Employees
256
Rev per Employee
$0.0
Show more

Is Biohaven Pharmaceutical Holding Company Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Biohaven Pharmaceutical Holding Company Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

20x Buy
91%
2x Hold
9%

Analyst Opinions

22 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

Buy
91%
Hold
9%

Financial data from Biohaven Pharmaceutical Holding Company Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 96 96
27% 27%
-
- Research and Development Expense 827 827
78% 78%
-
-915 -915
71% 71%
-
- Depreciation and Amortization 8.66 8.66
29% 29%
-
EBIT (Operating Income) EBIT -923 -923
71% 71%
-
Net Profit -889 -889
72% 72%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biohaven Pharmaceutical Holding Company Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biohaven Pharmaceutical Holding Company Ltd. Stock News

Neutral
GlobeNewsWire
about 9 hours ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Biohaven To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
one day ago
LOS ANGELES , Aug. 11, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Biohaven Ltd.
Neutral
PRNewsWire
one day ago
Cash, cash equivalents, marketable securities and restricted cash as of June 30, 2025, totaled approximately $408.2 million VYGLXIA NDA for spinocerebellar ataxia (SCA) PDUFA date 4Q2025, completed clinical trial inspections by FDA without observations or findings, and filing review remains ongoing MoDE and TRAP degrader platforms advance in clinical development, IgG reductions of up to 87% obs...
More Biohaven Pharmaceutical Holding Company Ltd. News

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Head office Virgin Islands, British
CEO Vladimir Coric
Employees 256
Founded 2022
Website www.biohaven.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today